Qué debe saber el médico de primaria sobre los nuevos marcadores en el cáncer de próstata

  1. A. Jalón Monzón 1
  2. M. Alvarez Múgica 2
  3. M. Jalón Monzón 3
  4. S. Escaf Barmadah 1
  1. 1 Hospital Universitario Central de Asturias (HUCA), Oviedo (Asturias), España
  2. 2 Hospital Valle del Nalón, Langreo (Asturias), España
  3. 3 Centro de Salud de Contrueces, Gijón (Asturias), España
Show affiliations +
Journal:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Year of publication: 2018

Issue: 6

Pages: 430-438

Type: Article

DOI: 10.1016/J.SEMERG.2017.12.005 DIALNET GOOGLE SCHOLAR

More publications in: Semergen: revista española de medicina de familia

Sustainable development goals

Abstract

La utilización del antígeno prostático específico como herramienta diagnóstica en el cribado del cáncer de próstata se ve reflejada en un incremento en la incidencia, un incremento en el diagnóstico de cánceres más precoces y un aumento en los tratamientos con intención curativa, aun a costa de un sobretratamiento. Sabemos, por datos recogidos en la literatura, que no todo paciente con antígeno prostático específico elevado necesita biopsia, y que no todo paciente con diagnóstico de cáncer de próstata necesita tratamiento. Con los nuevos marcadores prostáticos emergentes vamos a tratar de mejorar la especificidad del antígeno prostático específico en la zona gris (4-10 ng/ml) evitando biopsias innecesarias, de mejorar la sensibilidad en la detección de cáncer de próstata significante con antígeno prostático específico bajo y a intentar reducir el riesgo de sobretratamiento. Por otro lado, los biomarcadores pronósticos con test genómicos nos van a ayudar a elegir la mejor opción terapéutica para el paciente.

Bibliographic References

  • G.F. Carvalhal, D.S. Smith, D.E. Mager, C. Ramos, W.J. Catalona Digital rectal examination for detecting prostate cancer specific antigen levels of 4 ng/ml or less J Urol, 161 (1999), pp. 835-839 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • O.T. Okotie, K.A. Roehl, M. Han, S. Loeb, S.N. Gashti, W.J. Catalona Characteristics of prostate cancer detected by digital rectal examination only J Urol, 70 (2007), pp. 1117-1120 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • W.J. Catalona, J.P. Richie, J.B. de Kernion, F.R. Ahmann, T.L. Ratliff, B.L. Dalkin, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves J Urol., 152 (6 Pt 1) (1994), pp. 2031-2036 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar
  • I.M. Thompson, D.K. Pauler, P.J. Goodman, C.M. Tangen, M.S. Lucia, H.L. Parnes, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter N Engl J Med., 350 (2004 May 27), pp. 2239-2246 CrossRefGoogle Scholar
  • J.M. Cózar, B. Miñana, F. Gómez-Veiga, A. Rodríguez-Antolín, H. Villavicencio, A. Cantalaprieda, et al. Registro nacional de cácer de próstata 2010 en España Actas Urol Esp, 37 (2013), pp. 12-19 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • F.H. Schröder, J. Hugosson, M.J. Roobol, T.L. Tammela, S. Ciatto, V. Nelen, et al., ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study N Engl J Med., 360 (2009), pp. 1320-1328 View Record in ScopusGoogle Scholar
  • A.V. Taira, G.S. Merrick, R.W. Galbreath, H. Andreini, W. Taubenslag, R. Curtis, et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting Prostate Cancer Prostatic Dis., 13 (2010), pp. 71-77 CrossRefView Record in ScopusGoogle Scholar
  • C.M. Coley, M.J. Barry, C. Fleming, A.G. Mulley Early detection of prostate cancer Part I: Prior probability and effectiveness of tests. The American College of Physicians Ann Intern Med., 126 (1997 Mar 1), pp. 394-406 CrossRefView Record in ScopusGoogle Scholar
  • S. Sarkar, G. Horn, K. Moulton, A. Oza, S. Byler, S. Kokolus, et al. Cancer development, progression, and therapy: An epigenetic overview Intl J Mol Sci, 14 (2013), pp. 21087-21113 CrossRefView Record in ScopusGoogle Scholar
  • D. Jiang, Y. Shen, D. Dai, Y. Xu, C. Xu, H. Zhu, et al. Meta-analyses of methylation markers for prostate cancer Tumour Biol., 35 (2014), pp. 10449-10455 CrossRefView Record in ScopusGoogle Scholar
  • M. Schnekenburger, T. Karius, M. Diederich Regulation of epigenetic traits of the glutathione S-transferase P1 gene: From detoxification toward cancer prevention and diagnosis Front Pharmacol, 5 (2014), p. 170 View Record in ScopusGoogle Scholar
  • C. Goessl, M. Müller, R. Heicappell, H. Krause, K. Miller DNA-based detection of prostate cancer in blood urine, and ejaculates Ann N Y Acad Sci, 945 (2001), pp. 51-58 View Record in ScopusGoogle Scholar
  • M.L. Gonzalgo, C.P. Pavlovich, S.M. Lee, W.G. Nelson Prostate cancer detection by GSTP1 mathylation analysis of posbiopsy urine specimens Clin Cancer Res., 9 (2003), pp. 2673-2677 View Record in ScopusGoogle Scholar
  • N. Ashour, J.C. Angulo, G. Andres, R. Alelú, A. Gozález-Corpas, M.V. Toledo, et al. A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis Prostate, 74 (2014), pp. 1171-1182 CrossRefView Record in ScopusGoogle Scholar
  • R. Samsonov, T. Shtam, V. Burdakov, A. Glotov, E. Tsyrlina, L. Berstein, et al. Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: Application for prostate cancer diagnostic Prostate, 76 (2016), pp. 68-79 CrossRefView Record in ScopusGoogle Scholar
  • S. Kotb, A. Mosharafa, M. Essawi, H. Hassan, A. Meshref, A. Morsy Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer Tumour Biol, 35 (2014), pp. 12613-12617 CrossRefView Record in ScopusGoogle Scholar
  • S.A. Tomlins, D.R. Rhodes, S. Perner, S.M. Dhanasekaran, R. Mehra, X.W. Sun, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science, 310 (2005), pp. 644-648 CrossRefView Record in ScopusGoogle Scholar
  • S.A. Tomlins, S.M. Aubin, J. Siddiqui, R.J. Lonigro, L. Sefton-Miller, S.R. Miick, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA Sci Transl Med, 3 (2011) 94ra72 Google Scholar
  • B. Laxman, D.S. Morris, J. Yu, J. Siddiqui, J. Cao, R. Mehra, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer Cancer Res, 68 (2008), pp. 645-649 View Record in ScopusGoogle Scholar
  • J.A. Locke, P.C. Black Next generation biomarkers in prostate cancer Front Biosci (Landmark Ed), 21 (2016), pp. 328-342 View Record in ScopusGoogle Scholar
  • J. Sun, B.L. Chang, S.D. Isaacs, K.E. Wiley, F. Wiklund, P. Stattin, et al. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations Prostate., 68 (2008), pp. 1257-1262 CrossRefView Record in ScopusGoogle Scholar
  • R. Hu, T.A. Dunn, S. Wei, S. Isharwal, R.W. Veltri, E. Humphreys, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer Cancer Res., 69 (2009), pp. 16-22 View Record in ScopusGoogle Scholar
  • V.W. Ng, M. Koh, S.Y. Tan, P.H. Tan Is triple immunostaining with 34betaE12, p63, and racemase in prostate cancer advantageous? A tissue microarray study Am J Clin Pathol, 127 (2007), pp. 248-253 View Record in ScopusGoogle Scholar
  • P.A. Humphrey Diagnosis of adenocarcinoma in prostate needle biopsy tissue J Clin Pathol, 60 (2007), pp. 35-42 CrossRefView Record in ScopusGoogle Scholar
  • Z. Jiang, C. Li, A. Fischer, K. Dresser, B.A. Woda Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens Am J Clin Pathol, 123 (2005), pp. 231-236 View Record in ScopusGoogle Scholar
  • K.A. Iczkowski Current prostate biopsy interpretation. Criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains Arch Pathol Lab Med, 130 (2006), pp. 835-843 CrossRefView Record in ScopusGoogle Scholar
  • D.G. Bostwick, A. Pacelli, M. Blute, P. Roche, G.P. Murphy Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases Cancer, 82 (1998), pp. 2256-2261 CrossRefView Record in ScopusGoogle Scholar
  • D. Kahn, R.D. Williams, D.W. Seldin, J.A. Libertino, M. Hirschhorn, R. Dreicer, et al. Radioimmunoscintigraphy with 111 indium labeled CYT-356 for the detection of occult prostate cancer recurrence J Urol, 152 (5 Pt 1) (1994), pp. 1490-1495 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar
  • W.J. Rieter, T.E. Keane, M.A. Ahlman, C.T. Ellis, K.M. Spicer, L.L. Gordon Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer Clin Nucl Med, 36 (2011), pp. 872-878 View Record in ScopusGoogle Scholar
  • D. Kahn, R.D. Williams, M.J. Manyak, M.K. Haseman, D.W. Seldin, J.A. Libertino, et al., The ProstaScint Study Group 111 Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy J Urol, 159 (1998), pp. 2041-2046 CrossRefGoogle Scholar
  • T. Rizvi, Deng Ch, P.K. Rehm Indium-111 Capromab Pendetide (ProstaScint) demonstrates renal cell carcinoma and aortocaval nodal metastases from prostate adenocarcinoma World J Nucl Med, 14 (2015), pp. 209-211 CrossRefView Record in ScopusGoogle Scholar
  • A.M. El-Zawahry, H.S. Clarke, M.R. Eskridge, W. Rieter, G. Onicescu, E. Garrett-Mayer, et al. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate Urology, 76 (2010), pp. 1162-1167 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • E. Corey, S.K. Wegner, M.J. Corey, R.L. Vessella Prostate-specific antigen: Characterization of epitopes by synthetic peptide mapping and inhibition studies Clin Chem., 43 (1997), pp. 575-584 CrossRefView Record in ScopusGoogle Scholar
  • S.D. Mikolajczyk, L.S. Millar, T.J. Wang, H.G. Rittenhouse, L.S. Marks, W. Song, et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue Cancer Res., 60 (2000), pp. 756-759 View Record in ScopusGoogle Scholar
  • B.V. Le, C.R. Griffin, S. Loeb, G.F. Carvalhal, D. Kan, N.A. Baumann, et al. [-2] proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from bening disease in a prospective prostate cáncer screening study J Urol, 183 (2010), pp. 1355-1359 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar
  • L.J. Sokoll, M.G. Sanda, Z. Feng, J. Kagan, I.A. Mizrahi, D.L. Broyles, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2] proPSA: Improving prostate cáncer detection and correlating with cancer aggressiveness Cancer Epidemiol Biomarkers Prev, 19 (2010), pp. 1193-1200 View Record in ScopusGoogle Scholar
  • W.J. Catalona, A.W. Partin, M.G. Sanda, J.T. Wei, G.G. Klee, C.H. Bangma, et al. A multicenter study of [-2]pro-prostate-specific antigen combined with prostate-specific antigen and free prostate-specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/mL prostate-specific antigen range J Urology, 185 (2011), pp. 1650-1655 2 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar
  • G. Guazzoni, L. Nava, M. Lazzeri, V. Scattoni, G. Lughezzani, C. Maccagnano, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: Results of a prospective study in a clinical setting Eur Urol, 60 (2011), pp. 214-222 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • G. Guazzoni, M. Lazzeri, L. Nava, G. Lughezzani, A. Larcher, V. Scattoni, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer Eur Urol, 61 (2012), pp. 455-466 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • S. Isharwal, D.V. Makarov, L.J. Sokoll, P. Landis, C. Marlow, J.I. Epstein, et al. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program Urology, 77 (2011), p. 763 e1-6 View Record in ScopusGoogle Scholar
  • S. Loeb, W.J. Catalona The Prostate Health Index: A new test for the detection of prostate cancer Ther Adv Urol, 6 (2014), pp. 74-77 CrossRefView Record in ScopusGoogle Scholar
  • M.J. Bussemakers, A. van Bokhoven, G.W. Verhaegh, F.P. Smit, H.F. Karthaus, J.A. Schalken, et al. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res, 59 (1999), pp. 5975-5979 View Record in ScopusGoogle Scholar
  • J. Groskopf, S.M. Aubin, I.L. Deras, A. Blase, S. Bodruq, C. Clark, et al. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer Clin Chem, 52 (2006), pp. 1089-1095 CrossRefView Record in ScopusGoogle Scholar
  • A. Haese, A. de la Taille, H. van Poppel, M. Marberger, A. Stenzl, P.F. Mulders, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol, 54 (2008), pp. 1081-1088 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • S.M. Aubin, J. Reid, M.J. Sarno, A. Blase, J. Aussie, H. Rittenhouse, et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: Validation in the placebo arm of the dutasteride REDUCE trial J Urol, 184 (2010), pp. 1947-1952 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar
  • D. Hessels, J.A. Schalken The use of PCA3 in the diagnosis of prostate cancer Nat Rev Urol, 6 (2009), pp. 255-261 CrossRefView Record in ScopusGoogle Scholar
  • J. Ruíz-Aragón, S. Márquez-Peláez Evaluación del test PCA3 para el diagnóstico de cáncer de próstata: revisión sistemática y metaanálisis Actas Urol Esp, 34 (2010), pp. 346-355 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J. Rubio-Briones, A. Fernández-Serra, M. Ramírez, L. Rubio, A. Collado, J. Casanova, et al. Resultados del uso expandido del PCA3 score en una población española con sospecha de cáncer de próstata Actas Urol Esp, 35 (2011), pp. 589-596 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • N. Rodón, I. Trías, M. Verdú, R. Román, A. Domínguez, M. Calvo, et al. Valor diagnóstico y predictivo del estudio en orina del gen PCA3 para el manejo clínico de pacientes con antígeno prostático específico alterado Actas Urol Esp, 38 (2014), pp. 150-155 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • C.J. Rubio-Briones, R. Dumont, L. Rubio, A. Fernandez-Serra, I. Casanova-Salas, J. Dominguez-Escrig, et al. Prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program for early diagnosis of prostate cancer Eur Urol (2015) Abstract 315, EUA Congress Madrid 2015 Google Scholar
  • H. Van Poppel, A. Haese, M. Graefen, A. de la Taille, J. Irani, T. de Reijke, et al. The relationship between Prastate Cancer gene 3 (PCA3) and prostate cancer significance BJU Int, 109 (2012), pp. 360-366 View Record in ScopusGoogle Scholar
  • M.C. Gittelman, B. Hertzman, J. Bailen, T. Williams, I. Koziol, R.J. Henderson, et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: A prospective multicenter clinical study J Urol, 190 (2013), pp. 64-69 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar
  • J.T. Wei, Z. Feng, A.W. Partin, E. Brown, I. Thompson, L. Sokoll, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol, 32 (2014), pp. 4066-4072 View Record in ScopusGoogle Scholar
  • M. Auprich, F.K. Chun, J.F. Ward, K. Pummer, R. Babaian, H. Augustin, et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging Eur Urol, 59 (2011), pp. 96-105 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • A. Vickers, A. Cronin, M. Roobol, C. Savage, M. Peltola, K. Pettersson, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: An independent replication J Clin Oncol, 28 (2010), pp. 2493-2498 View Record in ScopusGoogle Scholar
  • S. Carlsson, A. Maschino, F. Schroder, C. Bangma, E.W. Steyerberg, T. van der Kwast, et al. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: Results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam Eur Urol, 64 (2013), pp. 693-699 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • R.J. Bryant, D.D. Sjoberg, A.J. Vickers, M.C. Robinson, R. Kumar, L. Marsden, et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study J Natl Cancer Inst, 107 (2015) djv095 Google Scholar
  • D.R. Shaffer, M.A. Leversha, D.C. Danila, O. Lin, R. Gonzalez-Espinoza, B. Gu, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer Clin Cancer Res, 13 (2007), pp. 2023-2029 View Record in ScopusGoogle Scholar
  • M.G. Krebs, R.L. Metcalf, L. Carter, G. Brady, F.H. Blackhall, C. Dive Molecular analysis of circulating tumour cells-biology and biomarkers Nat Rev Clin Oncol, 11 (2014), pp. 129-144 CrossRefView Record in ScopusGoogle Scholar
  • D. Lorente, D. Olmos, J. Mateo, D. Bianchini, G. Seed, M. Fleisher, et al. Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer Eur Urol, 70 (2016), pp. 985-992 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • D.C. Danila, G. Heller, G.A. Gignac, R. González-Espinosa, A. Anand, E. Tanaka, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer Clin Cancer Res, 13 (2007), pp. 7053-7058 View Record in ScopusGoogle Scholar
  • J.S. De Bono, H.I. Scher, R.B. Montgomery, C. Parker, M.C. Miller, H. Tissing, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res, 14 (2008), pp. 6302-6309 View Record in ScopusGoogle Scholar
  • K. Robinson, J. Creed, B. Reguly, C. Powell, R. Wittock, D. Klein, et al. Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay Prostate Cancer Prostatic Dis., 13 (2010), pp. 126-131 CrossRefView Record in ScopusGoogle Scholar
  • K.J. Wojno, F.J. Costa, R.J. Cornell, J.D. Small, E. Pasin, W. van Criekinge, et al. Reduced rate of repeated prostate biopsies observed in confirm MDx clinical utility field study Am Health Drug Benefits, 7 (2014), pp. 129-134 View Record in ScopusGoogle Scholar
  • J. Cullen, I.L. Rosner, T.C. Brand, N. Zhang, A.C. Tsiatis, J. Moncur, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer Eur Urol, 68 (2015), pp. 123-131 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • E.A. Klein, M. Cooperberg, C. Magi-Galluzzi, J.P. Simko, S.M. Falzarano, Y. Maddala, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling Eur Urol, 66 (2014), pp. 550-560 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J. Cuzick, D.M. Berney, G. Fisher, D. Mesher, H. Møller, J.E. Reid, et al., Transatlantic Prostate Group Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort Br J Cancer., 106 (2012), pp. 1095-1099 CrossRefView Record in ScopusGoogle Scholar
  • E.D. Crawford, M.C. Scholz, A.J. Kar, J.E. Fegan, A. Haregewoin, R.R. Kaldate, et al. Cell cycle progression score and treatment decisions in prostate cancer: Results from an ongoing registry Curr Med Res Opin., 30 (2014), pp. 1025-1031 CrossRefView Record in ScopusGoogle Scholar
  • M.R. Cooperberg, E. Davicioni, A. Crisan, R.B. Jenkins, M. Ghadessi, R.J. Karnes, et al. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort Eur Urol, 67 (2015), pp. 326-333 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M.F. Berger, M.S. Lawrence, F. Demichelis, Y. Drier, K. Cibulskis, A.Y. Sivachenko, et al. The genomic complexity of primary human prostate cancer Nature, 470 (2011), pp. 214-220 CrossRefView Record in ScopusGoogle Scholar
  • T.A. Bismar, M. Yoshimoto, R.T. Vollmer, Q. Duan, M. Firszt, J. Corcos, et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer BJU Int, 107 (2011), pp. 477-485 View Record in ScopusGoogle Scholar
  • T.H. Van der Kwast Prognostic prostate tissue biomarkers of potential clinical use Virchows Arch., 464 (2014), pp. 293-300 CrossRefView Record in ScopusGoogle Scholar
Data source: Dialnet